MSL1_GFP	RNAi
cyclin T1 shRNA	RNAi
Mass: 101.6 kg	biometrics
A549/ATCC	cell_line
AG09699	cell_line
AG11364	cell_line
Coriell GM15224	cell_line
GM17132	cell_line
GM17226	cell_line
GM17765	cell_line
GM17775	cell_line
LN18	cell_line
LuCaP69 xenograft	cell_line
LuCaP86.2 xenograft	cell_line
ND00397	cell_line
T98G glioma	cell_line
hgps-ipsc_2: Human HGPS fibroblasts AG01972, AG11498, AG06297, and normal fibroblasts GM00038 (9 year), AG05247 (87 year), AG09602 (92 year) were purchased from Coriell Cell Repository and reprogrammed using the protocol below.	cell_line
CD34 positive mononuclear	cell_type
CD49a positive	cell_type
Sca-1+,Lin-,AA4.1+,c-Kit++ FLHSC	cell_type
eNK cell	cell_type
epidermal keratinocyte, P-2 treatment	cell_type
lower-SP HSC	cell_type
mainly hippocampal neurons	cell_type
murine bone-marrow derived macrophages	cell_type
myeloid dendritic cell CD8-	cell_type
normal erythroid	cell_type
pro-B cell	cell_type
CDK4/6 inhibitor PD 0332991	compound
Clostridium perfringens toxin	compound
Cxcl12 75 nanomolar	compound
GR24 10 micromolar	compound
allyl alcohol 0.8 micromolar	compound
bucetin 300 micromolar	compound
chlorpyrifos 0.35 milligrams per kilogram per day	compound
clomipramine 40 micromolar	compound
cyproconazole 1.5 micromolar	compound
interleukin 1 beta	compound
labetalol 140 micromolar	compound
monensin 0.0000109 molar	compound
naproxen 400 micromolar	compound
nitrofurazone 10 micromolar	compound
serum amyloid A	compound
triamterene 1.2 micromolar	compound
E-LGCL-5	datasource
E-MEXP-403	datasource
GSE1922	datasource
GSE4636	datasource
Growing-Postselection	developmental_stage
DFS = 127 months	dfs_follow_up
prostate epithelial transit amplifying cells	differentiation_state
Ann Arbor stage: IIB	disease_staging
Unclassified	disease_staging
stage 4	disease_staging
Trypanosoma congolense infected	disease_state
moderate chronic allograft nephropathy	disease_state
Mrk-0	ecotype
OX0153:DZ twin	family_relationship
less than 20	generation
AP1::AtIPT4	genetic_modification
T-DNA knock out mutation	genetic_modification
sir2 control	genetic_modification
HCC227 lung adenocarcinoma	groups_369
HCC3153 breast cancer	groups_369
HCC515 lung adenocarcinoma	groups_369
SKMM1 multiple myeloma	groups_369
pc3 prostate cancer	groups_96
bronchial epithelia	groups_with_10_and_more_replicates
glucose-limiting medium	growth_condition
twice a week activity	growth_condition
Solid	histology
X-radiation 2 Grays	irradiate
del(11)(p12)	karyotype
unknown cytogenetics	karyotype
Drosophila yakuba	organism
cancer, Homogenized	organism_part
distal part small intestine	organism_part
flower + shoot apex	organism_part
lymphoid tissue	organism_part
media of abdominal aorta	organism_part
prefrontal cortex area 9	organism_part
proximal epiphysis of right fibula	organism_part
triceps	organism_part
ventral prostate	organism_part
B220Low sIgM+	phenotype
Txnip-deficient	phenotype
Txnip-deficient	phenotype
female	sex
B6-(Cg)TyrC-2J	strain_or_line
BXD31	strain_or_line
BY 4742 delta med31	strain_or_line
BY4742	strain_or_line
GABI-Kat_545D05	strain_or_line
PER-606	strain_or_line
SHEP-Tet21N	strain_or_line
a mixed 129 SvJ/C57Bl6 genetic background	strain_or_line
Oligofectamine with EGFP oligonucleotide	treatment
PM treated	treatment
epigallocatechin gallate 20 micromolar	treatment
mouse dorsal skin without tape stripping	treatment
